Skye is limitless

Unlocking the pharmaceutical potential of cannabinoids

We are a biopharmaceutical company engineering proprietary cannabinoid derivatives to treat glaucoma and other diseases with significant unmet medical needs

Our innovative approach to drug development enables us to transform cannabinoids into safer, more effective pharmaceutical agents. By advancing our novel drugs, we are working to bring important new medicines to market by unlocking the potential of cannabinoids.

Explore our technology

Driven by our passion and power to cure, we see the untapped opportunities ahead

Our team shares the experience, commitment, and passion to advance our ground-breaking technology through to commercialization.

Spotlight Articles

Insights from Skye’s CEO, Punit Dhillon

February 18, 2021

Insights from Skye’s CEO, Punit Dhillon

Skye Bioscience name change from Emerald Bioscience reflects ‘limitless’ strategy to treat glaucoma

January 27, 2021

Skye Bioscience name change from Emerald Bioscience reflects ‘limitless’ strategy to treat glaucoma

Shining a Light: In Recognition of Glaucoma Awareness Month

January 27, 2021

Shining a Light: In Recognition of Glaucoma Awareness Month

Resources